QB3 | GenomeWeb

QB3

NEW YORK (GenomeWeb News) — Mission Bio, a startup founded last year to commercialize PCR-activated cell sorting (PACS) technology developed at the University of California, San Francisco and the California Institute for Quantitative Biosciences (QB3), has been awarded a pair of National Institut

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

The expansion, which will quadruple the amount of incubator space that QB3 currently operates, is designed to quench the growing thirst of life science startups for incubator space at Mission Bay.

Approximately one year after Pfizer and the California Institute for Quantitative Biosciences inked a three-year, $9.5 million drug-discovery pact, the alliance is now overseeing seven projects combining scientists from various Pfizer sites and QB3-affiliated researchers at UC-San Francisco.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.